Bangladesh
· Delayed Price · Currency is BDT Silco Pharmaceuticals Statistics
Total Valuation
Silco Pharmaceuticals has a market cap or net worth of BDT 1.92 billion. The enterprise value is 1.87 billion.
| Market Cap | 1.92B |
| Enterprise Value | 1.87B |
Important Dates
The next estimated earnings date is Thursday, December 5, 2024.
| Earnings Date | Dec 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Silco Pharmaceuticals has 103.81 million shares outstanding. The number of shares has increased by 1.20% in one year.
| Shares Outstanding | 103.81M |
| Shares Change (YoY) | +1.20% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 45.23.
| PE Ratio | 45.23 |
| Forward PE | n/a |
| PS Ratio | 4.58 |
| PB Ratio | 0.84 |
| P/FCF Ratio | 56.51 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.02, with an EV/FCF ratio of 54.99.
| EV / Earnings | 43.71 |
| EV / Sales | 4.43 |
| EV / EBITDA | 12.02 |
| EV / EBIT | 33.39 |
| EV / FCF | 54.99 |
Financial Position
The company has a current ratio of 3.48, with a Debt / Equity ratio of 0.45.
| Current Ratio | 3.48 |
| Quick Ratio | 1.57 |
| Debt / Equity | 0.45 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.31 |
| Interest Coverage | 81.88 |
Financial Efficiency
Return on equity (ROE) is 1.83% and return on invested capital (ROIC) is 1.50%.
| Return on Equity (ROE) | 1.83% |
| Return on Assets (ROA) | 1.25% |
| Return on Capital (ROIC) | 1.50% |
| Revenue Per Employee | 1.36M |
| Profits Per Employee | 137,482 |
| Employee Count | 311 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.66 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.94% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -20.94% |
| 50-Day Moving Average | 19.87 |
| 200-Day Moving Average | 20.50 |
| Relative Strength Index (RSI) | 44.10 |
| Average Volume (20 Days) | 264,381 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Silco Pharmaceuticals had revenue of BDT 421.83 million and earned 42.76 million in profits. Earnings per share was 0.41.
| Revenue | 421.83M |
| Gross Profit | 126.47M |
| Operating Income | 55.98M |
| Pretax Income | 55.26M |
| Net Income | 42.76M |
| EBITDA | 151.72M |
| EBIT | 55.98M |
| Earnings Per Share (EPS) | 0.41 |
Balance Sheet
The company has 62.22 million in cash and 10.65 million in debt, giving a net cash position of 51.57 million or 0.50 per share.
| Cash & Cash Equivalents | 62.22M |
| Total Debt | 10.65M |
| Net Cash | 51.57M |
| Net Cash Per Share | 0.50 |
| Equity (Book Value) | 2.35B |
| Book Value Per Share | 21.96 |
| Working Capital | 761.61M |
Cash Flow
In the last 12 months, operating cash flow was 97.30 million and capital expenditures -63.31 million, giving a free cash flow of 33.99 million.
| Operating Cash Flow | 97.30M |
| Capital Expenditures | -63.31M |
| Free Cash Flow | 33.99M |
| FCF Per Share | 0.33 |
Margins
Gross margin is 29.98%, with operating and profit margins of 13.27% and 10.14%.
| Gross Margin | 29.98% |
| Operating Margin | 13.27% |
| Pretax Margin | 13.10% |
| Profit Margin | 10.14% |
| EBITDA Margin | 35.97% |
| EBIT Margin | 13.27% |
| FCF Margin | 8.06% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 1.62%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 1.62% |
| Dividend Growth (YoY) | -40.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 45.32% |
| Buyback Yield | -1.20% |
| Shareholder Yield | 0.42% |
| Earnings Yield | 2.21% |
| FCF Yield | 1.77% |
Stock Splits
The last stock split was on November 20, 2019. It was a forward split with a ratio of 1.1.
| Last Split Date | Nov 20, 2019 |
| Split Type | Forward |
| Split Ratio | 1.1 |